F

    Fennec Pharmaceuticals Inc (FENC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.35
    +0.08 (+0.65%)

    Market Cap: $430.27M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    43%(16/37)
    Avg Surprise
    -39.44%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.11
    Range$0.06 - $0.17
    5 analysts
    EPS RevisionsNo revisions (7d)
    4
    1
    30d
    EPS Estimate Drift
    90d ago$0.15+30.4%
    60d ago$0.07-37.5%
    30d ago$0.07-42.0%
    7d ago$0.12+4.2%
    Current$0.11
    Revenue Consensus
    $18M
    Range$18M - $20M
    6 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.22
    Range$0.08 - $0.40
    5 analysts
    Revenue Consensus
    $25M
    Range$23M - $26M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.22---
    Sep 26EST
    		-$0.11---
    Jun 26
    Reported Aug 11
    		$0.05$0.01+400.00%Beat+145.5%
    Mar 26
    Reported May 14
    		$0.01N/A-70.24%Miss+125.0%
    Dec 25
    Reported Mar 24
    		$-0.10$0.04-350.00%Miss-66.7%
    Sep 25
    Reported Nov 13
    		$-0.02$-0.02+0.00%Beat+90.5%
    Jun 25
    Reported Aug 14
    		$-0.11$-0.03-266.67%Miss+45.0%
    Mar 25
    Reported May 13
    		$-0.04$-0.08+50.00%Beat-109.8%
    Dec 24
    Reported Mar 10
    		$-0.06N/A+53.85%Beat+40.0%
    Sep 24
    Reported Nov 7
    		$-0.21$-0.08-162.50%Miss-200.0%
    Jun 24
    Reported Aug 13
    		$-0.20$0.02-1100.00%Miss+4.8%
    Mar 24
    Reported May 14
    		$0.41$-0.04+1125.00%Beat+278.3%
    Dec 23
    Reported Mar 21
    		$-0.10$-0.02-400.00%Miss+61.5%
    Sep 23
    Reported Nov 6
    		$-0.07$-0.13+46.15%Beat+77.4%
    Jun 23
    Reported Aug 3
    		$-0.21$-0.16-31.25%Miss-10.5%
    Mar 23
    Reported May 11
    		$-0.23$-0.19-21.05%Miss-64.3%
    Dec 22
    Reported Mar 30
    		$-0.26$-0.26+0.00%Beat-44.4%
    Sep 22
    Reported Nov 11
    		$-0.31$-0.19-63.16%Miss-93.8%
    Jun 22
    Reported Aug 12
    		$-0.19$-0.13-46.15%Miss-26.7%
    Mar 22
    Reported May 12
    		$-0.14$-0.14+0.00%Beat+26.3%
    Dec 21
    Reported Feb 28
    		$-0.18N/A-124.00%Miss-38.5%
    Sep 21
    Reported Nov 10
    		$-0.16$-0.14-14.29%Miss+33.3%
    Jun 21
    Reported Aug 10
    		$-0.15$-0.18+16.67%Beat+28.6%
    Mar 21
    Reported May 13
    		$-0.19$-0.38+50.00%Beat+0.0%
    Dec 20
    Reported Mar 30
    		$-0.13$-0.19+31.58%Beat+27.8%
    Sep 20
    Reported Nov 16
    		$-0.24$-0.19-26.32%Miss-166.7%
    Jun 20
    Reported Aug 5
    		$-0.21$-0.17-23.53%Miss+12.5%
    Mar 20
    Reported May 14
    		$-0.19$-0.18-5.56%Miss-46.2%
    Dec 19
    Reported Feb 14
    		$-0.18$-0.11-63.64%Miss-20.0%
    Sep 19
    Reported Nov 12
    		$-0.09N/A+52.63%Beat+35.7%
    Jun 19
    Reported Aug 9
    		$-0.24$-0.13-84.62%Miss-71.4%
    Mar 19
    Reported May 9
    		$-0.13$-0.14+7.14%Beat-44.4%
    Dec 18
    Reported Mar 13
    		$-0.15$-0.14-7.14%Miss-7.1%
    Sep 18
    Reported Nov 13
    		$-0.14$-0.14+0.00%Beat+6.7%
    Jun 18
    Reported Aug 13
    		$-0.14$-0.09-55.56%Miss-27.3%
    Mar 18
    Reported May 14
    		$-0.09$-0.11+18.18%Beat-12.5%
    Dec 17
    Reported Mar 26
    		$-0.14$-0.14+0.00%Beat-250.0%
    Sep 17
    Reported Nov 13
    		$-0.15$-0.04-275.00%Miss-
    Jun 17
    Reported Aug 11
    		$-0.11$-0.05-120.00%Miss-
    Mar 17
    Reported May 12
    		$-0.08N/AN/ABeat-
    Sep 16
    Reported Nov 14
    		$-0.04N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-205.83EV/EBITDA20.27x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-5.49%Operating Margin9.72%
    ROE-18.60%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage0.58x
    Current Ratio5.85xQuick Ratio5.66x
    Trading Statistics
    Beta1.07Avg Volume252.89K
    52-Week High$13.2552-Week Low$5.65

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$11.80
    SMA 20$11.61
    SMA 50$10.84
    SMA 200$8.55
    EMA 10$11.88
    EMA 20$11.55
    EMA 50$10.80
    EMA 200$9.10

    MACD

    Line: 0.43Signal: 0.40Hist: 0.03

    ADX

    ADX: 31.3+DI: 26.8-DI: 11.3

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down16.0
    PSAR$12.75

    Bollinger Bands

    Upper Band$12.90
    Lower Band$10.33
    %B Position2213%(Upper)
    Band Width0.79

    RSI (14-Day)

    Neutral
    61.2

    Momentum Oscillators

    Stoch %K53.7
    Stoch %D51.1
    Williams %R-38.0
    ROC (10d)4.4%
    Momentum0.52
    CCI (20d)100.1
    MFI (14d)48.5

    Volatility Measures

    ATR (14d)$0.68(5.5%)
    StdDev (20d)0.64
    Hist Vol82.7%(High)

    Volume Flow

    VWAP$12.37
    OBV8.8M
    AD Line-506.0K
    CMF (20d)0.029

    Volume Metrics

    Avg Vol (20d)259.6K
    Vol Ratio2.0x(High)
    VWMA (20d)$11.82

    Pivot Points

    R3$13.55
    R2$13.03
    R1$12.65
    Pivot Point$12.13
    S1$11.74
    S2$11.22
    S3$10.84

    Advanced Oscillators

    TSI16.91
    Ultimate Osc54.9
    KST140.49

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$17.87M$15.11M$13.78M$12.46M$9.65M$8.75M$7.92M$6.97M$7.26M$25.38M$9.73M$6.51M
    Cost of Revenue$721,000$570,000$1.76M$660,000$967,000$373,000$669,000$1.36M$608,000$550,000$685,000$331,000
    Gross Profit$17.15M$14.54M$12.01M$11.80M$8.69M$8.38M$7.26M$5.62M$6.65M$24.83M$9.05M$6.18M
    Operating Expenses$15.42M$14.66M$14.57M$11.99M$11.42M$9.19M$8.19M$10.82M$11.69M$11.08M$10.87M$7.20M
    R&D$118,000$49,000$20,000$29,000$107,000$94,000$50,000$97,000$157,000$3,000$32,000$12,000
    SG&A$4.64M$3.19M$8.44M$6.75M$6.53M$5.87M$4.20M$6.12M$6.86M$5.87M$6.97M$3.81M
    Operating Income$1.74M$-119,000$-2,553,000$-189,000$-2,732,000$-808,000$-934,000$-5,202,000$-5,039,000$13.74M$-1,818,000$-1,017,000
    Interest Income$287,000$339,000$228,000$152,000$171,000$236,000$399,000$516,000$570,000$197,000$0$102,000
    Interest Expense$3,000$7,000$2.36M$598,000$607,000$605,000$991,000$1.05M$1.07M$1.05M$1.21M$928,000
    Income Before Tax$2.02M$0$-4,680,000$-638,000$-3,152,000$0$-1,620,000$-5,735,000$-5,553,000$12.84M$-2,682,000$-1,867,000
    Income Tax Expense$42,000$0$0$0$0$0$0$0$0$0$0$0
    Net Income$1.97M$201,000$-4,786,000$-638,000$-3,152,000$-1,165,000$-1,985,000$-5,735,000$-5,553,000$12.84M$-2,682,000$-1,867,000
    EBITDA$1.76M$-105,000$-2,422,000$-180,000$-2,678,000$-757,000$-907,000$-5,159,000$-5,007,000$14.44M$-1,742,000$-969,000
    EBIT$1.73M$-131,000$-2,552,000$-192,000$-2,716,000$-796,000$-1,028,000$-5,205,000$-5,056,000$13.69M$-1,812,000$-1,041,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FENC

    News

    Fennec Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:FENC

    Fennec Pharmaceuticals Inc. (NASDAQ: FENC) generated $44.64 million USD in revenue last year, primarily from its Sodium Thiosulfate Injection segment. This marks a decrease from $47.54 million USD in the previous year. The United States was the sole significant geographical contributor to this revenue.

    TradingView•8/22/26•
    Neutral

    Jessica Vargas Appointed Vice President of Human Resources at Fennec Pharmaceuticals

    Fennec Pharmaceuticals Inc. has appointed Jessica Vargas as Vice President of Human Resources, bringing significant experience in HR business partnering and talent acquisition. Vargas will be responsible for the company’s people strategy, organizational development, and culture, supporting Fennec's mission to improve patient outcomes. Her extensive background includes roles at Amgen, Horizon, Graphic Packaging International, and Fenwal, Inc., spanning approximately 18 years in HR.

    https://hrtoday.in/•8/18/26•
    Somewhat-Bullish

    (FENC) and the Role of Price-Sensitive Allocations

    This article provides an AI-generated analysis of Fennec Pharmaceuticals Inc. (NASDAQ: FENC), indicating strong near and mid-term sentiment that could extend to the long term, with no resistance levels above the current price suggesting upside potential. It outlines specific institutional trading strategies (Long, Breakout, Short) with entry, target, and stop-loss levels, and a multi-timeframe signal analysis highlighting support and resistance. The analysis emphasizes positive sentiment and offers real-time signals and risk parameters.

    Stock Traders Daily•8/16/26•
    Bullish

    Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership

    Southpoint-related entities and individual John S. Clark have filed an amended Schedule 13G/A for Fennec Pharmaceuticals Inc. (FENC), indicating that they now beneficially own 0 Common Shares, representing 0% of the class. This filing signifies that their ownership is 5 percent or less, with no sole or shared voting or dispositive power. The filing was signed by John S. Clark II on August 14, 2026.

    Stock Titan•8/14/26•
    Neutral

    Fennec Pharmaceuticals (FENC) Stock Jumps As Profitability Raises A Bigger Question

    Fennec Pharmaceuticals (FENC) saw its stock jump 17% after reporting Q2 2026 profitability, with net income reaching US$2.0 million on US$17.9 million revenue. This shift from losses to profit and positive adjusted EBITDA has led to questions about the durability of this new profitability, especially given the company's reliance on its sole product, PEDMARK, and its cash position. While commercial execution shows promising growth, concerns about concentration risk and future cash timing remain significant watch points.

    Webull•8/14/26•
    Bullish

    Frequently Asked Questions About FENC

    Does FENC pay dividends?
    Fennec Pharmaceuticals Inc (FENC) does not currently pay a regular dividend.
    What is FENC's market cap?
    Fennec Pharmaceuticals Inc (FENC) has a market capitalization of $430.27M with a current stock price of $12.35.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In